Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXAM: XL184 in Medullary Thyroid Cancer
NCT00704730Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2008
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of cabozantinib in Medullary Thyroid Cancer (MTC), sponsored by Exelixis, Inc.. Started Jun 2008; status: completed.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT00704730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704730.